The diagnosis of the disease requires a comprehensive assessment platform such as clinical performance, imaging, laboratory testing and pathological activation. It can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnoses and treatment regimens. Treatment and treatment regimens for the management of the three-A syndrome require individualized development, usually including drug therapy, rehabilitation intervention, and regular follow-up to multiple-dimensional management.
In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of 3A syndrome.
The platform serves China International Medical Service System, a team of domestically and abroad authoritative experts in the field of blood tumours, who provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.